Literature DB >> 94374

Characterization of the coronary vasodilator and hemodynamic actions of monensin, a carboxylic ionophore.

R K Saini, R K Hester, P Somani, B C Pressman.   

Abstract

The effects of monensin on coronary blood flow (CBF) and other hemodynamic parameters were studied in anesthetized dogs. A dose-response relationship was established, and it was found that the lowest doses of monensin (5-25 micrograms/kg) produced a dose-dependent increase (3-5x) in CBF with a concomitant decrease in total peripheral resistance (TPR). Pretreatment with diphenhydramine, atropine, indomethacin, or propranolol resulted in no reduction in peak increase in CBF or in the duration of response to monensin. However, the response was partially blocked by aminophylline. Large doses (100 and 200 micrograms/kg) produced a dose-dependent increase in cardiac output, aortic pressure, and LV dP/dt max. The duration of these effects was dose-dependent, ranging from 60 to 120 min or longer. Heart rate remained unchanged with all doses of monensin. Pretreatment with propranolol, H87/07 (a cardioselective beta-blocker), and D-600 given alone or in combination significantly reduced, but did not completely abolish, the monensin-induced increase in LV dP/dt max and aortic pressure responses. The increase in CBF in the left anterior descending coronary artery was not significantly affected by these drug pretreatments. Thus, our studies indicate that monensin has two distinct pharmacological effects--in the lower dose range (less than 25 micrograms/kg) it produces a direct relaxation of the blood vessels resulting in an increase in CBF and a decrease in TPR; at high doses (greater than 25 micrograms/kg) it increases myocardial contractility and aortic blood pressure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94374     DOI: 10.1097/00005344-197901000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.

Authors:  R E Weishaar; D Kobylarz-Singer; B A Klinkefus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

2.  Improvement of cardiac performance by carboxylic ionophore monensin in greyhound and mongrel dogs.

Authors:  M Fahim; B C Pressman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

3.  The differential effect of calcium antagonists on the positive inotropic effects induced by calcium and monensin in cardiac preparations of rats and guinea-pigs.

Authors:  J G Hugtenburg; M J Mathy; J J Beckeringh; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-11       Impact factor: 3.000

4.  Ultrastructural alterations in the atrial myocardium of pigs with acute monensin toxicosis.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1984-03       Impact factor: 4.307

Review 5.  Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity.

Authors:  H H Mollenhauer; D J Morré; L D Rowe
Journal:  Biochim Biophys Acta       Date:  1990-05-07

6.  Stimulation of catecholamine secretion from cultured chromaffin cells by an ionophore-mediated rise in intracellular sodium.

Authors:  S J Suchard; F A Lattanzio; R W Rubin; B C Pressman
Journal:  J Cell Biol       Date:  1982-09       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.